• Laura Zima, Rebecca West, Paul Smolen, Nobuhide Kobori, Georgene Hergenroeder, HuiMahn A Choi, Anthony N Moore, John B Redell, and Pramod K Dash.
• Department of Neurological Surgery, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA.
• J. Neurotrauma. 2022 Oct 1; 39 (19-20): 127912881279-1288.

AbstractEpigenetic information is not permanently encoded in the DNA sequence, but rather consists of reversible, heritable modifications that regulate the gene expression profile of a cell. Epigenetic modifications can result in cellular changes that can be long lasting and include DNA methylation, histone methylation, histone acetylation, and RNA methylation. As epigenetic modifications are reversible, the enzymes that add (epigenetic writers), the proteins that decode (epigenetic readers), and the enzymes that remove (epigenetic erasers) these modifications can be targeted to alter cellular function and disease biology. While epigenetic modifications and their contributions are intense topics of current research in the context of a number of diseases, including cancer, inflammatory diseases, and Alzheimer disease, the study of epigenetics in the context of traumatic brain injury (TBI) is in its infancy. In this review, we will summarize the experimental and clinical findings demonstrating that TBI triggers epigenetic modifications, with a focus on changes in DNA methylation, histone methylation, and the translational utility of the universal methyl donor S-adenosylmethionine (SAM). Finally, we will review the evidence for using methyl donors as possible treatments for TBI-associated pathology and outcome.

21 keywords...

hide…